Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 2 · 100%Moderate 0 · 0%High 0 · 0%

Adverse event: secondary malignancies · Patients with early unfavourable or advanced stage HL

Escalated BEACOPP showed no clear difference in adverse event: secondary malignancies compared with chemotherapy including ABVD (low certainty).

1 finding from 1 review

Adverse event: secondary malignancies: AML or MDS · Patients with early unfavourable or advanced stage HL

Escalated BEACOPP may leads to higher adverse event: secondary malignancies: AML or MDS compared with chemotherapy including ABVD (low certainty).

1 finding from 1 review